Ford inks partnership with Mahindra & Mahindra to ramp up its position in India automotive industry
Category: #world  By Pankaj Singh  Date: 2017-09-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ford inks partnership with Mahindra & Mahindra to ramp up its position in India automotive industry

The American multinational carmaker, Ford Motor Company, has recently signed an agreement with Mahindra & Mahindra in a bid to use the latter’s operational skills to innovate advanced technologies in the ever-growing automotive market. Ford and Mahindra, through this alliance, aim to coordinate and team up in the disciplines of connected fleets, electric cars, and vehicles distribution within India for the next three years.

Officially, both the companies would commence work after the respective teams from Ford and Mahindra would meet up, and get down to discussions regarding future plans involving cost curtailment and parts purchasing. As India is one of the most vital revenue pockets of automotive market, Ford may be looking forward to consolidating its position strongly in the region. As per analysts, India may, in all likelihood, emerge as the third largest market for automotive sector by the end of 2020.

Ford has been ideating strategic plans to launch new luxury models in India’s billion-dollar automobile market, for the next five years. The company has already gained profits in China from the sales of the Lincoln luxury models and SUVs. Now, with its investment in India, the American company is looking forward to continuing its exponential growth graph in the Asia Pacific region.

For the record, this is Ford’s first major public announcement post Hackett’s appointment as the chief executive officer, who is also currently involved in Ford’s business operations in India. Recently, the company cancelled its dubious plans of moving the small car production plant from Michigan to Mexico. In a bid to fulfill the demand for vehicles across North America, Ford now plans to export fleets from their China based auto factory, where they have already invested USD 500 million. In the second quarter of 2017, Ford earned USD 143 million pretax profit in APAC region. In the last few years, the revenue of the automaker has increased by 30% subject to three strong business tactics, including effective scale, strong brand value, and competitive cost.

Jim Farley, Ford's global business president, has been quoted stating that Ford’s partnership with Mahindra & Mahindra is likely to prove highly beneficial for the automaker, owing to the fact that the latter encompasses a very powerful technical prowess as well as a strong distribution network. Through this collaboration, both these companies would now be able to develop electric cars and autonomous vehicles, which will culminate into high profit margins, letting the firms consolidate their positions in India automotive market. Given Mahindra’s successful track record in the automotive sector, Ford is likely to have made a lucrative investment in India, say experts.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...